Discovering a novel therapy for disorders that feature defects of the neuromuscular junction structure
<p><b>Background:</b> Congenital myasthenic syndromes (CMS) are a group of inherited disorders that affect signal transmission at the neuromuscular junction (NMJ) and share the clinical feature of fatigable muscle weakness. Downstream of tyrosine kinase 7 (DOK7) is a cytoplasmic-ad...
Main Author: | Panea, MD |
---|---|
Other Authors: | Beeson, D |
Format: | Thesis |
Language: | English |
Published: |
2020
|
Subjects: |
Similar Items
-
Antisense Oligonucleotide Gene Therapy for Neuromuscular Disorders
by: Ryan Gotesman
Published: (2018-11-01) -
Gene therapy for childhood neuromuscular and neurodegenerative disorders: An update
by: Prateek Kumar Panda
Published: (2019-01-01) -
Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back
by: Laurine Buscara, et al.
Published: (2020-11-01) -
Frequency and satisfaction of conventional and complementary or alternative therapies for neuromuscular disorders
by: Lene Änne Böhne, et al.
Published: (2023-10-01) -
Degeneration of Neuromuscular Junction in Age and Dystrophy
by: Rüdiger eRudolf, et al.
Published: (2014-05-01)